Literature DB >> 8451614

Subtype progression and pathophysiologic deterioration in early schizophrenia.

T H McGlashan1, W S Fenton.   

Abstract

It is important to elaborate what we know about the symptomatic, syndromal, and functional course of schizophrenia in order to test models for this illness. The sample of schizophrenic patients from the Chestnut Lodge followup study was subtyped using classical (modified DSM-III-R) criteria and deficit/nondeficit (Schedule for the Deficit Syndrome) criteria. During the first 5 years of manifest illness, the subtype phenomenologies were moderately stable. Instability consisted of a drift toward disorganization (hebephrenia) and nonspecificity (undifferentiated) among the classical subtypes, and toward the deficit subtype within that categorization. Over the same time, positive symptoms were relatively stable, but negative symptoms became significantly worse. Such changes probably reflect "deterioration" because they were associated with poorer functional outcome an average of 15 years later. These data dovetail with other reports in the literature and suggest a hierarchy of symptomatic/syndromal progression in early manifest schizophrenia that may reflect active deterioration processes at work. We suggest that any theory of schizophrenic pathophysiology must account for these patterns of symptom course.

Entities:  

Mesh:

Year:  1993        PMID: 8451614     DOI: 10.1093/schbul/19.1.71

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  21 in total

Review 1.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 2.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

3.  Rationale and parameters for medication-free research in psychosis.

Authors:  Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2006-02-03       Impact factor: 9.306

4.  Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge.

Authors:  Thomas H McGlashan; William T Carpenter
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

5.  Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial.

Authors:  Shaun M Eack; Deborah P Greenwald; Susan S Hogarty; Susan J Cooley; Ann Louise DiBarry; Debra M Montrose; Matcheri S Keshavan
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

6.  Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.

Authors:  Masakuni Horiguchi; Kayleen E Hannaway; Adesewa E Adelekun; Karu Jayathilake; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2012-06-27       Impact factor: 7.853

Review 7.  The effects of aging on insight into illness in schizophrenia: a review.

Authors:  Philip Gerretsen; Eric Plitman; Tarek K Rajji; Ariel Graff-Guerrero
Journal:  Int J Geriatr Psychiatry       Date:  2014-07-23       Impact factor: 3.485

Review 8.  Is active psychosis neurotoxic?

Authors:  T H McGlashan
Journal:  Schizophr Bull       Date:  2006-08-16       Impact factor: 9.306

9.  Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing.

Authors:  Rajendra A Morey; Seniha Inan; Teresa V Mitchell; Diana O Perkins; Jeffrey A Lieberman; Aysenil Belger
Journal:  Arch Gen Psychiatry       Date:  2005-03

Review 10.  Psychoradiology: The Frontier of Neuroimaging in Psychiatry.

Authors:  Su Lui; Xiaohong Joe Zhou; John A Sweeney; Qiyong Gong
Journal:  Radiology       Date:  2016-11       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.